Study of the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Subjects With Amnestic Mild Cognitive Impairment
This study is currently recruiting participants.
Verified June 2011 by QR Pharma Inc.
Sponsor:
QR Pharma Inc.
Information provided by:
QR Pharma Inc.
ClinicalTrials.gov Identifier:
NCT01072812
First received: February 19, 2010
Last updated: June 11, 2011
Last verified: June 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This trial will determine the pharmacokinetics of Posiphen® in both plasma and CSF after a 10-day treatment period with Posiphen® in subjects with amnestic MCI. The effects of this treatment on biomarkers will also be determined in CSF, whole blood, and plasma or serum as primary pharmacodynamic (PD) objectives.
| Condition | Intervention | Phase |
|---|---|---|
|
Alzheimer's Disease Amnestic Mild Cognitive Impairment |
Drug: Posiphen® tartrate capsules |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-Label, Two-Stage Study to Evaluate the Pharmacokinetics and Pharmacodynamics of POSIPHEN® in Plasma and CSF After a 10-Day Treatment Period in Subjects With Amnestic Mild Cognitive Impairment |
Resource links provided by NLM:
Further study details as provided by QR Pharma Inc.:
Primary Outcome Measures:
- Pharmacokinetics [ Time Frame: 10 days ] [ Designated as safety issue: No ]To determine the pharmacokinetics (PK) of Posiphen® and its metabolites in plasma and CSF after a 10-day treatment period with Posiphen®.
- Pharmacodynamics [ Time Frame: 10 days ] [ Designated as safety issue: No ]To assess the effects of a 10-day treatment period with Posiphen® on the levels of amyloid precursor protein (APP), amyloid β protein 40 (Aβ40), amyloid β protein 42 (Aβ42), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE) in plasma and CSF from subjects with amnestic MCI.
Secondary Outcome Measures:
- Biomarkers [ Time Frame: 10 days ] [ Designated as safety issue: No ]To assess the effects of a 10-day treatment period with Posiphen® on the levels of amino terminal fragment (N-APP), tau (T-tau), phosphorylated tau (P-tau), nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), interleukin 1B (IL1B), S-100B protein (S-100B) in plasma or serum and CSF, and the activities of AChE and BChE in whole blood or plasma and CSF from subjects with amnestic MCI.
- Safety [ Time Frame: 10 days ] [ Designated as safety issue: Yes ]To determine the safety and tolerability of a 10-day treatment period with Posiphen®.
| Estimated Enrollment: | 30 |
| Study Start Date: | February 2010 |
| Estimated Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Posiphen® tartrate capsules |
Drug: Posiphen® tartrate capsules
Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
Other Name: Posiphen® Tartrate
|
Eligibility| Ages Eligible for Study: | 55 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Males or post-menopausal females aged 55 to 80 years, inclusive.
- Must have Mild Cognitive Impairment (MCI) (amnestic subtype) according to Petersen's criteria (2004).
- Mini Mental Status Examination (MMSE) score should be ≥24.
- Must score below a pre-determined cut-off score on the logical memory II delayed paragraph recall sub-test of the Wechsler Memory Scale Revised (WMS-R).
- Must have a Clinical Dementia Rating of 0.5 with a memory box score of 0.5 or 1.0.
- Modified Hachinski score of less than or equal to 4.
- Hamilton Depression rating scale (HAMD17) score of less than or equal to 12 with a score of 0 on items 1, 2, and 3 (depressed mood, feelings of guilt, and suicidal ideation).
- No evidence of current suicidal ideation or previous suicide attempt in past 2 years as evaluated in the Columbia Suicidality Checklist.
- MRI scans within 12 months prior to screening, or per screening MRI, without evidence of infection, infarction, or other focal lesions and without clinical symptoms suggestive of intervening neurological disease.
- No clinically significant abnormalities in the lumbar spine should be present on a lumbar X-ray that would contraindicate lumbar puncture.
- Adequate visual and hearing ability (physical ability to perform all the study assessments).
- Normal B12, folic acid, and thyroid function tests (thyroid stimulating hormone [TSH], free T4, and free T3).
- Do not require nursing home care.
Exclusion Criteria:
- Any significant neurologic disease other than amnestic MCI, or history of significant head trauma followed by persistent neurologic deficits or known structural brain abnormalities.
- Major depression, schizophrenia or another major psychiatric disorder as described in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) within the past 2 years.
- Psychotic features, agitation, or behavioral problems within the last 3 months which could lead to difficulty complying with the protocol.
- History of alcohol or substance abuse or dependence within the past 2 years.
- Subjects with any febrile illness within 1 week prior to the CSF collection.
- Subjects who have history of migraine headaches and any other type of headaches of at least moderate severity more than twice per month.
- Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol or pose potential risk to the subjects.
- Use of medications prohibited by the study.
- Any clinically significant laboratory abnormalities.
- Subjects with infection or inflammation of the skin or skin disease at or in proximity to the lumbar puncture site.
- History of lumbar spine surgery or chronic low back pain (CLBP).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01072812
Contacts
| Contact: Mark T Leibowitz, MD | (210) 635-1500 | mleibowitz@cedracorp.com |
Locations
| United States, Texas | |
| CEDRA Clinical Research, LLC | Recruiting |
| San Antonio, Texas, United States, 78217 | |
| Contact: Mark T Leibowitz, MD 210-635-1500 mleibowitz@cedracorp.com | |
| Principal Investigator: Mark T Leibowitz, MD | |
Sponsors and Collaborators
QR Pharma Inc.
Investigators
| Principal Investigator: | Mark T Leibowitz, MD | CEDRA |
More Information
No publications provided
| Responsible Party: | Maria Maccecchini, PhD, QR Pharma, Inc. |
| ClinicalTrials.gov Identifier: | NCT01072812 History of Changes |
| Other Study ID Numbers: | QR 12001 |
| Study First Received: | February 19, 2010 |
| Last Updated: | June 11, 2011 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by QR Pharma Inc.:
|
Alzheimer's Amnestic Mild Cognitive Impairment Pharmacokinetics Pharmacodynamics Biomarkers |
Additional relevant MeSH terms:
|
Alzheimer Disease Cognition Disorders Dementia Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Tauopathies Neurodegenerative Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 16, 2013